Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.56 |
| ▸ | RAB9A | P51151 | 10/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | AHR | P35869 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.49 |
| ▸ | RELA | Q04206 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3746152 | 0.90 | NPC1 (0.59) | NPC1SMN1; SMN2RAB9AS1PR1MAPT | |
| SCHEMBL3743148 | 0.80 | SMN1; SMN2 (0.68) | NPC1SMN1; SMN2RAB9AKDM4EHPGD | |
| SCHEMBL13417178 | 0.78 | S1PR1 (0.62) | NPC1SMN1; SMN2RAB9AKDM4ETSHR | |
| SCHEMBL3747069 | 0.77 | NPC1 (0.60) | NPC1SMN1; SMN2RAB9AKDM4EHPGD | |
| Dimethylamine SCHEMBL7961743 | 0.76 | SMN1; SMN2 (0.67) | NPC1SMN1; SMN2RAB9AKDM4EHPGD | |
| SCHEMBL58788 | 0.74 | NR1H4 (0.81) | NPC1SMN1; SMN2RAB9AKDM4EHPGD | |
| SCHEMBL28889002 | 0.73 | S1PR1 (0.58) | NPC1SMN1; SMN2RAB9AKDM4EHPGD | |
| SCHEMBL23524328 | 0.73 | NPC1 (0.49) | NPC1SMN1; SMN2RAB9AKDM4EHPGD | |
| SCHEMBL30355372 | 0.73 | NPC1 (0.49) | NPC1SMN1; SMN2RAB9AKDM4EHPGD | |
| SCHEMBL13524984 | 0.72 | S1PR1 (0.62) | NPC1SMN1; SMN2RAB9AKDM4ES1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2109364-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008076356-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076356-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280876-A1 | Novel oxadiazole compounds | S1PR3, S1PR1, S1PR2 | NPC1 1268/4885SMN1; SMN2 3564/4885RAB9A 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.